Summary
OncoResponse Inc (OncoResponse) focuses on the discovery, development and commercialization of therapeutic antibodies for the treatment of cancer. The company’s lead program includes ONCR-201, an anti-EMP2 fully-human monoclonal antibody, which is developed for female malignancies. It utilizes I-STAR platform, to interrogate the human memory B-cell repertoire of cancer patients. OncoResponse works in partnership with MD Anderson Cancer Center, Theraclone Sciences, Oregon Health & Scienc
Read More
- List of Tables
- OncoResponse Inc, Pharmaceuticals & Healthcare, Key Facts 2
- OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
- OncoResponse Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
- OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
- OncoResponse Inc, Deals By Therapy Area, 2012 to YTD 2018 8
- OncoResponse Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
- OncoResponse Raises USD40 Mi
Read More
- Table of Contents
- Table of Contents 3
- List of Tables 4
- List of Figures 4
- OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
- OncoResponse Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
- OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
- OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
- OncoResponse Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Read More